Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership ...

OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said the European Medicines ...

TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on ...

Steven Holtzman, the retired chief executive of Decibel Therapeutics and a former executive vice president at Cambridge-based ...

Healthcare analytics company PurpleLab joined the Network Advertising Initiative. Biogen and Neomorph announced a multi-target research collaboration to discover and develop molecular glue degraders ...